These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25337754)

  • 1. Shortening treatment for tuberculosis--to basics.
    Warner DF; Mizrahi V
    N Engl J Med; 2014 Oct; 371(17):1642-3. PubMed ID: 25337754
    [No Abstract]   [Full Text] [Related]  

  • 2. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.
    Alffenaar JW; Gumbo T; Aarnoutse R
    N Engl J Med; 2015 Feb; 372(6):576. PubMed ID: 25651257
    [No Abstract]   [Full Text] [Related]  

  • 3. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.
    Sellier PO; Clevenbergh P; Bergmann JF
    N Engl J Med; 2015 Feb; 372(6):577. PubMed ID: 25651258
    [No Abstract]   [Full Text] [Related]  

  • 4. Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment.
    Sterling TR
    Evid Based Med; 2015 Aug; 20(4):128-9. PubMed ID: 25926523
    [No Abstract]   [Full Text] [Related]  

  • 5. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.
    Gillespie SH; Mendel CM;
    N Engl J Med; 2015 Feb; 372(6):577. PubMed ID: 25651256
    [No Abstract]   [Full Text] [Related]  

  • 6. [Respiratory fluoroquinolones and pulmonary tuberculosis treatment when the main drugs are ineffective].
    Lazareva NB; Khaĭmenova TIu; Khaĭmenov AIa
    Antibiot Khimioter; 2008; 53(5-6):14-20. PubMed ID: 19069177
    [No Abstract]   [Full Text] [Related]  

  • 7. Donor-derived tuberculosis (TB): isoniazid-resistant TB transmitted from a lung transplant donor with inadequately treated latent infection.
    Jensen TO; Darley DR; Goeman EE; Shaw K; Marriott DJ; Glanville AR
    Transpl Infect Dis; 2016 Oct; 18(5):782-784. PubMed ID: 27459235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sparfloxacin in combined therapy for pulmonary tuberculosis].
    Sokolova GB; Khaĭmenova TIu; Lazareva IaV; Khaĭmenov AIa
    Antibiot Khimioter; 2008; 53(5-6):21-7. PubMed ID: 19069178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Floracide, a Russian 3rd generation fluoroquinolone in complex therapy of tuberculosis].
    Sokolova GB; Kirtaeva OV; Lazareva IaV; Tsybanev AA
    Antibiot Khimioter; 2008; 53(5-6):28-31. PubMed ID: 19069179
    [No Abstract]   [Full Text] [Related]  

  • 10. [Fully supervised ambulatory short-course chemotherapy with an intermittent regimen for newly diagnosed smear-positive pulmonary tuberculosis].
    Xu RX
    Zhonghua Jie He He Hu Xi Za Zhi; 1987 Oct; 10(5):261-3, 307. PubMed ID: 3131029
    [No Abstract]   [Full Text] [Related]  

  • 11. Quantitative bacteriology in the clinical testing of new antituberculosis drugs.
    Wallace AT
    Tubercle; 1969 Mar; 50():Suppl:47-9. PubMed ID: 4990183
    [No Abstract]   [Full Text] [Related]  

  • 12. [The relation between bacilli negative conversion rate and the number of combined sensitive antituberculous drugs in intermittent administration of rifampicin for severe pulmonary tuberculosis].
    Tamura M; Yamazaki A; Tamura T; Takano S; Yamazaki M
    Kekkaku; 1973 Jul; 48(7):297-302. PubMed ID: 4200058
    [No Abstract]   [Full Text] [Related]  

  • 13. The advantages of the antituberculosis regimens which include Sinerdol-EH, a new tuberculostatic of rifampicin-type.
    Păunescu E
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1983; 32(1):33-42. PubMed ID: 6312533
    [No Abstract]   [Full Text] [Related]  

  • 14. Rifampin in the treatment of drug-resistant mycobacterium tuberculosis infections.
    Vall-Spinosa A; Lester W; Moulding T; Davidson PT; McClatchy JK
    N Engl J Med; 1970 Sep; 283(12):616-21. PubMed ID: 4988918
    [No Abstract]   [Full Text] [Related]  

  • 15. [Drug-resistant pulmonary tuberculosis at the penitentiaries].
    Kononets AS
    Probl Tuberk Bolezn Legk; 2008; (12):60-3. PubMed ID: 19227326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Synthesis and tuberculostatic activity of fluoridized 3-Z-hydrazine-2-benzoyl acrylates and their cyclization products].
    Kravcheko MA; Nosova EV; Lipunova GN; Chasovskikh OM; Sokolov VA; Charushin VN
    Probl Tuberk Bolezn Legk; 2003; (7):49-52. PubMed ID: 12939881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis.
    Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2004 Apr; 23(4):414-5. PubMed ID: 15081096
    [No Abstract]   [Full Text] [Related]  

  • 19. [Place of bacteriological examination in the treatment of tuberculosis].
    Gyselen A
    Acta Tuberc Pneumol Belg; 1972; 63(4):405-8. PubMed ID: 4206438
    [No Abstract]   [Full Text] [Related]  

  • 20. [Toward a modern treatment of pulmonary tuberculosis. 2. Bacteriologic and pharmacologic bases and short-term treatment].
    Zegaya M
    Tunis Med; 1984 Nov; 62(7):487-94. PubMed ID: 6442475
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.